4.6 Article

Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8+ T Cells

期刊

CANCER IMMUNOLOGY RESEARCH
卷 7, 期 3, 页码 476-486

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-18-0182

关键词

-

资金

  1. NCI [K12 CA157688]
  2. ACS [IRG-97-219-14, IRG-16-185-17]
  3. HHS, NIH, NCI [K12 CA157688]
  4. [ACS IRG-97-219-14]
  5. [ACS IRG-16-185-17]

向作者/读者索取更多资源

Tumor antigen-specific T cells rapidly lose energy and effector function in tumors. The cellular mechanisms by which energy loss and inhibition of effector function occur in tumor-infiltrating lymphocytes (TILs) are ill-defined, and methods to identify tumor antigen-specific TILs that experience such stress are unknown. Processes upstream of the mitochondria guide cell-intrinsic energy depletion. We hypothesized that a mechanism of T-cell-intrinsic energy consumption was the process of oxidative protein folding and disulfide bond formation that takes place in the endoplasmic reticulum (ER) guided by protein kinase R-like endoplasmic reticulum kinase (PERK) and downstream PERK axis target ER oxidoreductase 1 (ERO1a). To test this hypothesis, we created TCR transgenic mice with a T-cellspecific PERK gene deletion (OT1(+) Lckcre(+) PERKf/f, PERK KO). We found that PERK KO and T cells that were pharmacologically inhibited by PERK or ERO1a maintained reserve energy and exhibited a protein profile consistent with reduced oxidative stress. These T-cell groups displayed superior tumor control compared with T effectors. We identified a biomarker of ER-induced mitochondrial exhaustion in T cells as mitochondrial reactive oxygen species (mtROS), and found that PD-1(+) tumor antigenspecific CD8(+) TILs express mtROS. In vivo treatment with a PERK inhibitor abrogated mtROS in PD-1(+) CD8(+) TILs and bolstered CD8(+) TIL viability. Combination therapy enabled 100% survival and 71% tumor clearance in a sarcoma mouse model. Our data identify the ER as a regulator of T-cell energetics and indicate that ER elements are effective targets to improve cancer immunotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据